Atypical femoral fracture in a bisphosphonate-na ïve patient on denosumab for osteoporosis

ConclusionThe patient underwent intramedullary nailing of the femur and denosumab was ceased. This is only the fifth case reported of atypical femoral fracture in a bisphosphonate-na ïve patient receiving denosumab for osteoporosis. Although rare, physicians should maintain a high index of suspicion for atypical femoral fracture in a patient taking denosumab even without prior bisphosphonate exposure.
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research